HomeTrialNCT07280221
🔬NCT07280221ENROLLING BY INVITATION

WEgovy Real World Assessment of Weight Loss in Korea

Study Summary

This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice. The purpose of this study is to investigate the change in body weight and other clinical characteristics related to body weight in patients living with obesity. Participants will be treated with Wegovy (semaglutide) as prescribed by their doctor, in accordance with normal clinical practice. The study will last for about 52 weeks.

Conditions
Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment500 participants
Primary Completion
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.367037+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.